"Matching" the "mismatch" repair deficient prostate cancer with immunotherapy.

"Matching" the "mismatch" repair deficient prostate cancer with immunotherapy.
Clin Cancer Res. 2020 Jan 03;:
Authors: Schweizer MT, Yu EY
Abstract
Mismatch repair gene mutations are uncommon in advanced prostate cancer; however, in those harboring these alterations, immune checkpoint blockade can be effective. As such, assays that can accurately identify these men are critically important. Cell-free circulating tumor DNA-based sequencing approaches appear to be one viable approach for identifying these patients.
PMID: 31900277 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 2, 2020 Category: Cancer & Oncology Authors: Schweizer MT, Yu EY Tags: Clin Cancer Res Source Type: research